Harnessing Dendritic Cells for Tumor Antigen Presentation

Cancers

Stefan Nierkens¹ 

[1] Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen 6525 GA, The Netherlands; E-Mail:

关键词: dendritic cell;    tumor antigen;    antigen presentation;    antigen processing;   

DOI  :  10.3390/cancers3022195

来源: mdpi

【 摘 要 】

Dendritic cells (DC) are professional antigen presenting cells that are crucial for the induction of anti-tumor T cell responses. As a consequence, research has focused on the harnessing of DCs for therapeutic interventions. Although current strategies employing ex vivo-generated and tumor-antigen loaded DCs have been proven feasible, there are still many obstacles to overcome in order to improve clinical trial successes and offset the cost and complexity of customized cell therapy. This review focuses on one of these obstacles and a pivotal step for the priming of tumor-specific CD8⁺ and CD4⁺ T cells; the in vitro loading of DCs with tumor antigens.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.